Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

NCT04698915 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

177

Enrollment

INDUSTRY

Sponsor class

Stopped Futility Analysis

Conditions

SBRT
Borderline Resectable Pancreatic Cancer
Unresectable Pancreatic Cancer

Interventions

DRUG: Drug GC4711
DRUG: Placebo

Sponsor

Galera Therapeutics, Inc.